Join Zoom Meeting
https://mc-meet.zoom.us/j/95861380114?pwd=WThqQ2ZxM1l5SlVVV1lWNUN4WTl0UT09

Meeting ID: 958 6138 0114
Passcode: 188969

Education
Allen J. Aksamit, Jr. M.D.
"Progressive Multifocal Leukoencephalopathy: Past and Present

Learning objectives: 
Upon conclusion of this activity, participants will be able to:

• Demonstrate Progressive Multifocal Leukoencephalopathy (PML) as a focal viral CNS infection by JC virus
• Estimate how changes in patient survival of PML have occurred depending on the cause of underlying immunosuppression
• Detect PCR for JC virus in CSF is specific for pathologically significant PML
• Prescribe natalizumab  and B-cell depleting treatment for multiple sclerosis have a significant risk of PML
• Categorize that exacerbation of neurologic symptoms can be indicative of immune reconstitution inflammatory syndrome (IRIS) with treatment for PML
• Debate that no effective treatment exists for PML beyond reversing immunosuppression, but recent checkpoint inhibitors and T-cell therapies  have been used anecdotally or experimentally

Dr. Aksamit does not have any relevant financial relationships to disclose and does not intend to discuss any off-label/investigative use of Pharmaceuticals or Instruments.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.